Across TCGA pan-cancer cohorts, VGLL3 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of VGLL3’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where VGLL3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types VGLL3 is over-expressed in tumor, although a few such as LSCC and PDAC show the opposite, repressed pattern.

LSCC, PDAC, and LUAD are the cancer types where VGLL3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in VGLL3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	−1.000	<.001	4	view →
PDAC	Male	All	−0.838	.018	4	view →
LUAD	All	All	−1.045	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: VGLL3 RNA expression & survival · all VGLL3 data types